{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:16:34Z","timestamp":1779894994742,"version":"3.53.1"},"reference-count":80,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Coronavirus disease 2019 (COVID\u201019) pandemic has dramatically impacted the health risk and management of patients with lymphoma. Clinical evaluations on the impact of COVID\u201019 on lymphoma patients are currently limited however, reports have shown a correlation with specific variants and more severe COVID\u201019 complications and higher mortality rates relative to other disease states and age\u2010matched populations. During peak pandemic periods this created a concerning management problem for clinicians and raised the question of how different immunocompromised states increase COVID\u201019\u2010associated risk and provided insights into how immunity interacts with the circulating variant, including the effects of low virulent variants in vaccinated lymphoma populations. Treatment management approaches, polymerase chain reaction tests and rapid antigen screening guidelines have been offered in an attempt to reduce the risk of harm to lymphoma patients, particularly prior to and following bone marrow or stem cell transplant. Here we systematically review the current literature to provide a novel global perspective on incidence, mortality, management and rapid antigen test (RAT) screening for COVID\u201019, in patients with various subtypes of lymphoma. Furthermore, lessons learned from emerging variants that continue to inform evolving lymphoma management and public health policies are addressed across these associated matters.<\/jats:p>","DOI":"10.1111\/ejh.13926","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:33:52Z","timestamp":1674138832000},"page":"457-469","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Global reported impacts of <scp>COVID<\/scp>\u201019 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic"],"prefix":"10.1111","volume":"110","author":[{"given":"Esther K.","family":"Elliott","sequence":"first","affiliation":[{"name":"Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences Queensland University of Technology (QUT)  Kelvin Grove Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hensen","sequence":"additional","affiliation":[{"name":"Icon Cancer Centre  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa M.","family":"Haupt","sequence":"additional","affiliation":[{"name":"Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences Queensland University of Technology (QUT)  Kelvin Grove Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-5475","authenticated-orcid":false,"given":"Lyn R.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Genomics Research Centre, Centre for Genomics and Personalised Health, School of Biomedical Sciences Queensland University of Technology (QUT)  Kelvin Grove Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"e_1_2_17_2_1","unstructured":"World Health Organization.Weekly epidemiological update on COVID\u201019 2022.https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242606799"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"e_1_2_17_5_1","unstructured":"Global Cancer Observatory.World GLOBOCAN2021.https:\/\/gco.iarc.fr\/projects."},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.014"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32526"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0480-x"},{"issue":"2","key":"e_1_2_17_9_1","first-page":"200","article-title":"Immunodeficiency\u2010associated lymphoproliferative disorders","volume":"12","author":"Knowles DM","year":"1999","journal-title":"Mod Pathol"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13469"},{"key":"e_1_2_17_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33160"},{"key":"e_1_2_17_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17027"},{"key":"e_1_2_17_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00970-7"},{"key":"e_1_2_17_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.601709"},{"key":"e_1_2_17_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26404"},{"key":"e_1_2_17_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3"},{"key":"e_1_2_17_17_1","volume-title":"SARS\u2010CoV\u20102 Variants","author":"World Health Organization","year":"2022"},{"key":"e_1_2_17_18_1","unstructured":"National Centre Biotechnology Information Pubmed\u2010National Library of Medicine.https:\/\/pubmed.ncbi.nlm.nih.gov\/."},{"key":"e_1_2_17_19_1","unstructured":"Australian Health Protection Principal Committee.Australian Health Protection Principal Committee statement on rapid antigen testing for current high community prevalence environment 2022.https:\/\/www.health.gov.au\/news\/ahppc-statement-on-rapid-antigen-testing-for-current-high-community-prevalence-environment"},{"key":"e_1_2_17_20_1","unstructured":"Food and Drug Administration.COVID\u201019\u2010Related Guidance Documents for Industry FDA Staff and Other Stakeholders 2019.https:\/\/www.fda.gov\/emergency\u2010preparedness\u2010and\u2010response\/coronavirus\u2010disease\u20102019\u2010covid\u201019\/covid\u201019\u2010related\u2010guidance\u2010documents\u2010industry\u2010fda\u2010staff\u2010and\u2010other\u2010stakeholders."},{"key":"e_1_2_17_21_1","unstructured":"European Centre for Disease Prevention and Control.Options for the use of rapid antigen detection tests for COVID\u201019 in the EU\/EEA\u2014first update 2021.https:\/\/www.ecdc.europa.eu\/en\/publications-data\/options-use-rapid-antigen-tests-covid-19-eueea-first-update."},{"key":"e_1_2_17_22_1","unstructured":"European Medicines Agency.European Hematology Association guidelines. Recommendations for Specific Hematologic Malignancies 2022https:\/\/ehaweb.org\/covid-19\/covid-19-recommendations\/recommendations-for-specific-hematologic-malignancies\/."},{"key":"e_1_2_17_23_1","unstructured":"National Health Service.Regular Rapid Coronavirus Tests.https:\/\/www.nhs.uk\/conditions\/coronavirus\u2010covid\u201019\/testing\/regular\u2010rapid\u2010coronavirus\u2010tests\u2010if\u2010you\u2010do\u2010not\u2010have\u2010symptoms\/."},{"key":"e_1_2_17_24_1","unstructured":"World Health Organization.Antigen\u2010detection in the diagnosis of SARS\u2010CoV\u20102 infection 2021.https:\/\/www.afro.who.int\/search\/google-cse?keys=rapid+antigen+tests."},{"key":"e_1_2_17_25_1","unstructured":"American Society of Hematology.COVID\u201019 Resources 2022.https:\/\/www.hematology.org:443\/covid-19."},{"key":"e_1_2_17_26_1","unstructured":"Ljungman.P MM Styczynski.J de laCamara.R.Recommendation on: Coronavirus Disease COVID\u201019 European Group for Blood and Marrow Transplantation 2020.https:\/\/www.ebmt.org\/covid-19-and-bmt."},{"key":"e_1_2_17_27_1","unstructured":"Swissmedic.Joint Guidance of Swissmedic and swissethics on the management of clinical trials with medicinal drug products in Switzerland during the COVID\u201019 pandemic 2020.https:\/\/ecrin.org\/sites\/default\/files\/Swiss_Guidance_COVID\u201019_v2.0_26.03.2020%20(2).pdf."},{"key":"e_1_2_17_28_1","unstructured":"Food and Drug Administration.Food and Drug Administration Guidance on Conduct of Clinical Trials of Medical Products During the COVID\u201019 Public Health Emergency 2021.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/fda\u2010guidance\u2010conduct\u2010clinical\u2010trials\u2010medical\u2010products\u2010during\u2010covid\u201019\u2010public\u2010health\u2010emergency."},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1741327"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.705948"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508199"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0388-x"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.02.009"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0678"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.005"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16896"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13101927"},{"issue":"1","key":"e_1_2_17_39_1","first-page":"59","article-title":"SARS\u2010COV\u20102 virus triggers immune antitumor response in a lymphoma patient","volume":"42","author":"Rudolphi\u2010Solero T","year":"2021","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i3.10141"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17116"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05275-6"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01267"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2323"},{"key":"e_1_2_17_45_1","unstructured":"Centers for Disease Control and Prevention.2022.COVID Data Tracker 2022.https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions."},{"key":"e_1_2_17_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1861277"},{"key":"e_1_2_17_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30310-7"},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"e_1_2_17_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0516"},{"key":"e_1_2_17_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"e_1_2_17_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100549"},{"key":"e_1_2_17_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"e_1_2_17_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000538"},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04328-4"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005691"},{"key":"e_1_2_17_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30251-9"},{"key":"e_1_2_17_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01177-0"},{"key":"e_1_2_17_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824"},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26209"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1110748"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103104"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.002"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.544"},{"key":"e_1_2_17_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006288"},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0836-7"},{"key":"e_1_2_17_68_1","unstructured":"National Institute of Health U.S National Library of Medicine.Clinical Trials 2022.2022https:\/\/clinicaltrials.gov\/ct2."},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14859"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.049"},{"key":"e_1_2_17_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.04.002"},{"key":"e_1_2_17_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01466-0"},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1858789"},{"key":"e_1_2_17_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30429-4"},{"key":"e_1_2_17_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00177-z"},{"key":"e_1_2_17_76_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.070"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0948-7"},{"key":"e_1_2_17_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00169-1"},{"key":"e_1_2_17_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"e_1_2_17_80_1","unstructured":"World Health Organization.Strategy to Achieve Global COVID\u201019 Vaccination by mid\u20102022.2021."},{"key":"e_1_2_17_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25856"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13926","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:23:34Z","timestamp":1692649414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/ejh.13926"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13926","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"2022-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}